Introduction
Chronic heart failure (CHF) is a complex clinical syndrome that results from various structural or functional impairment of ventricular filling or ejection of blood. 1 It is a leading cause of death in industrialized nations, especially in the aging population. 2 The lifetime risk for developing CHF has been estimated to range from 20 to 33% worldwide, and approximately half of the patients diagnosed with CHF will die within 5 years, despite all the advances in therapies. 3 The aetiology of CHF has been categorized into ischaemic or non-ischaemic cardiomyopathy, e.g. dilated cardiomyopathy (DCM). 1 In contrast to the therapeutic developments in cardiac revascularization therapy for ischaemic cardiomyopathy, conceptual novel clinical approaches to treat DCM remain scarce. 4 Therefore, research focussed on novel mechanics and pharmacologic therapies for DCM is urgently needed. 5 Recently, it has been suggested that non-coding RNAs (ncRNAs) such as microRNAs (miRNAs) play important roles in CHF initiation and progression at the posttranscriptional level. 6 However, mammalian genomes are comprised of not only a small fraction of miRNAs, but also a large number of long non-coding RNAs (lncRNAs). 7 LncRNAs are conventionally described as transcripts which are over 200 nucleotides long, lacking protein coding potential. 7 Studies have suggested that lncRNAs participate in diverse cellular processes ranging from chromatin modification and RNA stability to translational control. 8 A fascinating aspect of lncRNAs is their versatility. 9 LncRNAs regulate specific gene expression by targeting production, splicing, decay, or translation of target mRNAs. Biochemically, lncRNAs employ RNA-RNA, RNA-DNA, or RNA-protein interactions to exert their activities. 10 LncRNAs play key roles in diverse physiological (X-chromosome inactivation, 11 embryonic development, 12 etc.), and pathological processes (such as cancer, 13 metabolic disorders, 14 identified many aberrantly expressed lncRNAs in CHF models. 15, 16 Moreover, overexpression/knockdown of specific lncRNAs significantly affected the outcomes of cardiac hypertrophy in mouse. 17, 18 However, in contrast to the growing knowledge of lncRNAs in mouse models, less is known about their roles in human heart. Most lncRNAs lack sequence conservation among species, which renders the extension of the findings derived from murine models to humans problematic. 19 Recently, several papers have performed RNA-seq to determine lncRNAs expression in human hearts. 15, 16 One paper identified 145 differentially expressed lncRNAs in ICM human hearts, while the other identified 679 (ICM) and 570 (NICM) differentially expressed lncRNAs with heart failure. In order to measure lowly expressed lncRNAs, very deep sequencing is needed. Increasing read depths may significantly improve the accuracy of transcripts that are expressed at low levels. 20 LncRNAs are poorly expressed as their general properties, 7, 21, 22 Recently, it was reported that microarrays have better performance characteristics for low abundance RNAs (such as lncRNAs) than RNAseq. 23 Moreover, in a clinical study, microarrays were chosen over RNAseq because of, among other considerations, the better sensitivity. 24 As there is no paper using microarray to study lncRNAs expression on DCM human hearts, our study evaluated lncRNAs expression profiles in hearts from controls and DCM induced CHF patients. Moreover, by analysing their tissue/cell expression patterns and performing loss of function studies, we attempted to identify possible functions of identified lncRNAs in DCM induced CHF. These results provide new understanding of the mechanisms and potential therapeutic targets for DCM induced heart failure in the future.
Methods

Study approval
All human samples (heart, liver, lung, colon, adipose, and aorta) were collected in Tongji Hospital (Wuhan, China) between January 2012 and October 2014. The study was approved by the Ethics Review Board of Tongji Hospital and Tongji Medical College, and conformed to the principles of the Declaration of Helsinki. Informed consents were signed by the subjects recruited in the study or by the immediate family members in case of incapacity.
In the screening cohort, left ventricular biopsy samples were obtained from 14 DCM-induced CHF patients ( Table 1 ) during heart transplantation surgery and 10 control donors (accident victims). In the validation cohort, heart samples from another 6 patients (see Supplementary material online, Table S1 ) with DCM induced CHF and 6 control subjects were recruited.
RNA extraction
Total RNA was isolated using TRIzol (Invitrogen) and purified with RNeasy mini kit (QIAGEN) according to manufacturer's instructions. RNA quality and quantity were measured by Nanodrop spectrophotometer (ND-1000, Nanodrop Technologies) and RNA integrity was determined by gel electrophoresis.
LncRNA microarray
LncRNA microarray analysis was performed by Kangcheng Bio-tech Inc (Shanghai, China). About 30,586 lncRNAs and 26,109 coding transcripts can be detected by the third-generation lncRNA microarrays (V3.0). Briefly, mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was amplified and transcribed into fluorescent cRNA (RNA derived from cDNA through standard RNA synthesis) along the entire length of the transcripts without 3' bias utilizing a random priming method (Arraystar Flash RNA Labeling Kit, Arraystar). The labelled cRNAs were purified by RNeasy Mini Kit (Qiagen). The concentration and specific activity of the labelled cRNAs (pmol Cy3/lg cRNA) were measured by NanoDrop ND-1000. One microgram of each labelled cRNA was fragmented by adding 5 ll of 10 Â Blocking Agent and 1 ll of 25 Â Fragmentation Buffer, then the mixture was heated at 60 C for 30 min. Finally, 25 ll of 2 Â GE Hybridization buffer was added to dilute the labelled cRNA. ). Agilent Feature Extraction software (version 11.0.1.1) was used to analyse acquired array images. Quantile normalization and subsequent data processing were performed with the GeneSpring GX v12.1 software package (Agilent Technologies). After normalization, statistical differentially expressed lncRNAs between two groups were identified through fold change and P-value. The threshold value for significance used to define up-regulation or down-regulation of lncRNAs was a fold change >2, as well as with a P-value of < 0.05 calculated by t-test. 25 The detailed information of all dys-regulated lncRNAs including fold change, P value, FDR, probe sequences and associated genes were all listed in Supplementary material online, Excel S1.
RNA-sequencing
RNA-seq and data analyses were performed by Personal Biotechnology Co., Ltd (Shanghai, China). 
Quantitative real-time PCR
lncRNA tissue and cell expression pattern
Quantitative RT-PCR was performed to assess the expression pattern of lncRNAs in different human tissues (heart, aorta, colon, lung, liver, and adipose). U6 snRNA was served as a loading control among different tissues as described. [27] [28] [29] The expression of other organs were represented using a fold change relative to the value 1 of the heart (n = 3).
To assess the expression patterns of lncRNAs in different cells, human cardiac myocytes (HCMs, ScienCell research laboratories), human cardiac fibroblasts-adult ventricular (HCF-av, ScienCell research laboratories) and human cardiac microvascular endothelial cells (HCMECs, ScienCell research laboratories) were utilized. U6 snRNA was served as a loading control among different cardiac cell types as described. 6 The expression of other cells were represented using a fold change relative to the value 1 of the HCMs (n = 3).
Cell culture and transfection
HCMs used in this experiment are from a single foetal donor, not pooled (ScienCell research laboratories, Lot no. 18387). HCM cells were maintained in cardiac myocyte medium (CMM, ScienCell research laboratories), according to the instruction manual. CMM consists of basal medium, foetal bovine serum (FBS), cardiac myocyte growth supplement, and penicillin/streptomycin solution. HCF-av cells were maintained at fibroblast medium-2 (FM-2, ScienCell research laboratories) which contained fibroblast growth supplement-2 and FBS. HCMECs were maintained in endothelial cell medium (ECM). ECM consists of basal medium, FBS, endothelial cell growth supplement and penicillin/ streptomycin solution. Human umbilical vein endothelial cells (HUVECs)
were obtained from American Type Tissue Collection and cultured as described in our published articles. 30, 31 In all experiments, each single batch of these primary cells was used without any passage culture. siRNAs (50 nM) were transfected into cells by Lipofectamine RNAiMAX (Life Technologies, CA). pCMV6-TAF10 plasmid (Cat. No. RC204138) was purchased from Origene Technologies (Rockville, MD). All siRNAs and random control were designed and synthesized by Riobio Co., Ltd (Guangzhou, China). The sequences are presented in the Supplementary material online, Table S3 2
.8 Transcription factor prediction
To predict transcription factors that bind to promotor region of lncRNAs, TRANSFAC database (http://www.gene-regulation.com/ index2.html) was employed. The 5' promoter region (about 0-2,000 bps) of DNA for each lncRNA (top four up-regulated) was selected for prediction. The predicted transcription factor binding sites were listed in Supplementary material online, Excel S2.
Chromatin immunoprecipitation-PCR assay
Chromatin immunoprecipitation (ChIP) assay was performed to evaluate TAF10 targeting at specific lncRNA promoters using Pierce Magnetic ChIP Kit (Thermo Fisher Scientific, Cat no. 26157) according to the instruction manual. Briefly, minced human hearts were fixed with 1% formaldehyde and then quenched by addition of glycine. The samples were homogenized in lysis buffer and sonicated to generate chromatin samples. Then samples were incubated with anti-TA10 antibody (Merck Millipore, Cat no. 1078) or normal control IgG at 4 C. Antibodychromatin complexes were then incubated with ChIP Grade Protein A/ G-magnetic beads which were collected by a magnetic stand. After washing, the immunoprecipitated DNA was eluted and purified. Realtime PCR was then performed using primers targeting the promoter regions of lncRNAs. Primers are listed in Supplementary material online, Table S2 .
CCK-8 assay
Treated HCM cells were incubated in 10% WST-8 dye (Beyotime Institute of Biotechnology, Shanghai, China) diluted in normal culture medium at 37 C until visual colour conversion occurred in 96-well culture plates. The number of viable cells was assessed by measurement of absorbance at 450 nm using a microplate reader.
EdU assay
Treated HUVEC cells were labelled with EdU (5-ethynyl-2'-deoxyuridine) according to the manufacturer's protocol (Ribobio Corporation, Guangzhou, China).
Cell apoptosis assays
Apoptosis was detected using the Annexin V-fluorescein isothiocyanate (FITC)/PI Apoptosis Detection Kit (BD, Shanghai, China). Briefly, cells were resuspended in binding buffer, incubated with FITC-conjugated Annexin V and propidium iodide according to the manufacturer's protocol, and then analysed with FACStar Plus flow cytometer (BD, Shanghai, China). Annexin V-positive and PI-positive cells were considered undergoing apoptosis.
lncRNA profile in dilated cardiomyopathy
Tube formation
Cells were plated in a 96-well plate pre-coated with 100 ml growth factor-reduced Matrigel Matrix (Corning Life Sciences, Corning, NY). After 8 h incubation, images were taken by inverted microscope.
Migration
Transwell inserted with 8 lm-pore size membrane (Corning Life Sciences, Corning, NY) were used. The cells were incubated for 12 h in the upper chamber and then fixed and stained with crystal violet. After the upper surface of transwell insert membrane was wiped, the migrated cells were counted in five random fields by microscopy.
Statistical analysis
Data were presented as mean ± S.E.M. (n was noted in specific figure legends). Student's t-tests and the analysis of variance (ANOVA) with Bonferroni post hoc analysis were performed to determine statistical significance between different groups. Pearson's correlation analyses were used to evaluate the relationships between lncRNAs and clinical parameters. In all cases, statistical significance was defined as P < 0.05.
Results
Study design
The overall study concept consisted of an initial profiling phase of lncRNAs in hearts from DCM patients compared with controls. Subsequent analyses were conducted to select lncRNAs for function investigations: (i) fragments per kilobase of exon per million fragments mapped (FPKM) > 0 in the heart; (ii) successfully validated; (iii) conservation potential; (iv) non-coding potential; (v) LncRNA loss-of-function assay; (vi) transcription factor prediction; and (vii) correlation with heart function. The flowchart of this study was shown in Figure 1 .
lncRNA profile in DCM hearts
To identify DCM-related lncRNAs, heart samples from 10 controls and 14 DCM patients were recruited for profile analysis. Table 1 provides the baseline characteristics of the patients. lncRNAs expressions were presented in a scatter plot and volcano plot as DCM vs. control, according to the definition that the threshold value for the significance used to define up-regulation or downregulation of lncRNAs was a fold change >2, as well as with a P value of < 0.05 (Figure 2A and B) . Scatter plots of lncRNA profile identified 313 (139 up-regulated and 174 down-regulated) differentially expressed lncRNAs (Figure 2A) . The top 20 modulated lncRNAs (fold changes) were indicated by a different (green) colour code in volcano plot of cardiac lncRNA profile ( Figure 2B ). Heat map revealed distinct expression patterns of lncRNAs between control and DCM group, and the top 20 up-regulated (fold changes) and 20 down-regulated (fold changes) lncRNAs, respectively, were presented in Figure 2C .
In order to validate the data obtained from microarray analysis, qPCR was applied to a selected subset of the differentially expressed lncRNAs. From the top 20 upregulated and 20 down-regulated lncRNAs, 10 were selected for validation as they were expressed in heart supported by NONCODE database (see Supplementary material online, Tables S4 and S5). Out of the 10 selected lncRNAs (4 up-regulated and 6 downregulated), 8 were successfully validated in a second cohort ( Figure 2D ), which indicated a high reliability of our profile.
Six of the eight successfully validated lncRNAs were conserved in mouse or zebrafish (see Supplementary material online, Tables S4 and S5), which facilitated the animal studies in the future. More importantly, only four of the eight successfully validated lncRNAs were suggested non-coding potential in all five databases (see Supplementary material online, Tables S4 and S5). From these 4 lncRNAs, RP11-544D21.2 and XLOC_014288 were selected in further function analysis based on fold change. The genomic loci of RP11-544D21.2 and XLOC_014288 were shown in Supplementary material online, Figure S1 .
We have also compared our microarray data to published RNA-seq performed on human failing hearts (see details in the discussion section).
Tissue distribution and cell distribution of RP11-544D21.2 and XLOC_014288
We further analysed the tissue expression of lncRNA RP11-544D21.2 and XLOC_014288. Normal human organs including heart, liver, lung, adipose, colon, and aorta were employed. The results showed that RP11-544D21.2 and XLOC_014288 were universally expressed ( Figure  3A and B, see Supplementary material online, Tables S4 and S5). Furthermore, we analysed these lncRNAs expression patterns in three kinds of human-derived primary cells, HCMs, HCF-av, and HCMECs. The expressions in other cells were represented using a fold change relative to the value 1 of the HCMs. All the cells were confirmed by qRT-PCR of the markers for each cell type (TNT for HCMs, COL1A1 for HCFs and CD31 for HCMECs) ( Figure 3C) . Results showed that RP11-544D21.2 and XLOC_014288 were expressed in HCMs, HCFs and HCMECs universally ( Figure 3D) . The lack of cell type-specificity indicated that these lncRNAs might have complex roles in multiple types of cardiac cells.
lncRNA loss-of-function assay
By using specific siRNAs against RP11-544D21.2 and XLOC_014288, we investigated their roles in HCMs, HCFs and HCMECs, respectively. As a lncRNA is very hard to be knockdown by regular siRNAs, we the use of Smart Silencer. 32 Each lncRNA Smart Silencer is a mixture of three siRNAs and three antisense oligonucleotides. We found that Smart Silencer treatment led to a specific down-regulation of their target lncRNAs (see Supplementary material online, Figure S2A ).
Next, we assessed the regulation of lncRNAs on three types of cells in the heart by RNA-seq and pathway analyses, respectively. In HCMs, HCFs, and HCMECs, RP11-544D21.2 [dilated cardiomyopathy related lncRNA (DCRL)] and XLOC_014288 knockdown led to Figure S2B) . Furthermore, pathway analysis was performed to gain the function of these lncRNAs in three heart cells ( Figure 4A-L) . We summarized the pathways regulated by RP11-544D21.2 (DCRL) and XLOC_014288 in three different heart cells (see Supplementary material online, Tables S6 and S7). Specifically, arrhythmogenic right ventricular cardiomyopathy pathway, hypertrophic cardiomyopathy (HCM) pathway and DCM-related genes were upregulated in si-RP11-544D21.2 treated HCMs. Antigen processing and presentation pathway and cell adhesion molecules pathway-related genes were down-regulated in si-RP11-544D21.2 treated HCMs. Moreover, pathways such as cell cycle, focal adhesion and ECM-receptor interaction were regulated by RP11-544D21.2 in both HCMs and HCFs. Very interestingly, si-RP11-544D21.2 treatment led to upregulation of TNF signalling pathway and MAPK signalling pathway in HCMs, but led to downregulation of the same pathways in HCFs.
These data revealed the complicated, coordinated sometimes even contradictory regulation of lncRNAs in multiple cell types.
RP11-544D21.2 knockdown decreased tube formation and migration of HUVECs
As primary human heart cells, HCMs, HCFs and HCMECs, were very hard to obtain, we first utilized HUVECs to investigate the role of RP11-544D21.2 and XLOC_014288 in endothelial cells. GO analysis revealed downregulation of angiogenesis related genes ( Figure 5A -D, see Supplementary material online, Table S8 ) in si-RP11-544D21.2 and si-XLOC_014288 treated HCMECs, and thus, we analyse tube formation and cell migration in HUVECs. The results showed that down-regulation of RP11-544D21.2 (DCRL) impaired tube formation and cell migration in HUVECs ( Figure 5E and F) . Apoptosis was increased in si-RP11-D544D21.2-treated HUVECs, while the proliferation was unaltered by RP11-544D21.2 and XLOC_014288 knockdown ( Figure 5G and H).
Transcription factors for up-regulated lncRNAs
To gain insight into the transcription factors binding to certain lncRNA, TRANSFAC database was employed, and the 5' promoter region ($ -2,000 -0 bps) of DNA from each lncRNA (top four up-regulated) was loaded. Most of the transcription factors predicted to target promoter regions of up-regulated lncRNAs remained unaltered in DCM, except for transcription factor II D (TFIID), one subunit of RNA polymerase II pre-initiation complex. TFIID is composed of several subunits called TATA-binding protein-associated factors (TAFs), which were significantly dys-regulated in DCM ( Figure 5A ). We found significant increases in TAF10 and TAF1C, and decreases in TAF1L, TAF5, and TAF11 in DCM compared with control, while other TAFs remained unaltered ( Figure 6A) . These data suggested an unbalanced composition of TFIID in CHF. To identify whether these TAFs were co-expressed with lncRNAs, correlation analysis was performed. TAF10 was positively correlated to all the top four up-regulated lncRNAs ( Figure 6B ), but it was not correlated to the down-regulated lncRNAs (data not shown). Chip-PCR assay further confirmed the binding of TAF10 on the promoter region of these two lncRNAs in human heart ( Figure 6C) . Next, we used siRNAs to knock-down TAF10, and decreased TAF10 mRNA level was detected in HCMs ( Figure 6D) . Meanwhile, two of the four up-regulated lncRNAs were down-regulated by si-TAF10 treatment ( Figure 6D) . However, only one of the four up-regulated lncRNA was activated in TAF10 overexpressed cardiomyocytes ( Figure 6E) . The discrepancy between the numbers of regulated lncRNAs in TAF10 gain-and loss-function assays indicated that TAF10 was necessary but not sufficient for inducing certain lncRNAs.
Association between lncRNAs and severity of CHF
Further analyses were performed to identify the possible association between the lncRNAs (top four up-regulated and four down-regulated) and the clinical parameters from patients, which indicated the severity of heart function. Correlation analysis between cardiac lncRNA expression levels and left ventricular ejection fraction (LVEF) was performed. Interestingly, we found significant correlations with LVEF (P < 0.05) in Figure S3 ), while the other six lncRNAs showed no significant correlation. However, circulating levels of these eight lncRNAs in control and DCM patients were undetectable (qPCR, 40 cycles), indicating poor potential of these lncRNAs releasing into plasma.
Discussion
Although lncRNAs are well studied in animal heart failure models, their functions in human remain elusive. We thus performed microarray analysis directly on human hearts and identified a number of dys-regulated lncRNAs in DCM patients. Moreover, we performed RNA-seq and pathway analyses to reveal the function of selected lncRNAs in HCMs, HCFs and HCMECs. The differentially expressed lncRNAs as well as their potential targets may lead to a new insight into the mechanisms and treatment strategies for DCM in the future.
In order to estimate the sensitivity and reliability of our study, we first used the mRNA component of our microarrays to compare with published papers. About 40% of our top 15 up-regulated and 15 downregulated mRNAs have been successfully identified by RNA-seq on DCM or ICM induced failing heart (see Supplementary material online, Table S9 ), which is very similar to a previous article demonstrating that the correlation between RNA-seq and microarray varies from 9.9% (low expression gene) to 50.9% (medium expression genes). 33 Given the fact that there is no published lncRNA microarray data in failing human heart, we compared our lncRNA microarray to published lncRNA-seq papers. 15, 16 Surprisingly, none of our top 20 up-regulated and 20 down-regulated lncRNAs have been identified by the two lncRNA profile in dilated cardiomyopathy RNA-seq papers. We speculate the reasons are as follows: (i) in the published papers, the authors generated an annotation database that includes lncRNAs from the NONCODE v3.0 human ncRNA database. Our array has successfully detected down-regulation of several HOX transcript antisense RNAs in DCM induced failing heart. However, cardiac HOX transcript antisense RNAs were not easily be identified by RNA-seq as they have a FPKM value equals 0 in the heart (data from NONCODE database). Nowadays, heart-specificity makes lncRNAs more attractive for targeted therapies. In this study, though some lncRNAs showed a relative higher abundance in heart compared with other tissues, none of these selected lncRNAs were heart-specific. In fact, strictly, organ-specific lncRNAs are very few, the majority of lncRNAs detected in heart are widely expressed in other tissues. Also, the functions of these lncRNAs are still unknown. Our present work provided several most dysregulated lncRNAs in DCM, and uncovered their regulation on DCMrelated genes, serving as intriguing therapeutic targets. In our opinion, non-tissue specificity of an lncRNA does not equal to non-promising therapeutic target. Significantly dysregulated lncRNAs, which are not tissue specific, were also promising therapeutic targets. For example, lncRNA APF (autophagy promoting factor) was reported to regulate autophagy and myocardial infarction. An ameliorated myocardial function was observed in the mice treated with APF-siRNA on I/R injury. However, lncRNA APF was not heart specific, which was also expressed in other tissues. 38 How these dys-regulated lncRNAs to be linked to DCM? DCM has been understood to be a genetic disease. Mutations reported to cause DCM have been identified in >30 genes (such as TTN, MYBPC3, TTNT, TNNI, MYH7, MHY6, etc.). 39 However, in a large kindred harbouring the same DCM mutation, some siblings can have profound decreases in LV systolic function accompanied by overt heart failure, whereas others might have no evidence of heart failure at all. The mechanisms that drive penetrance and variable expressivity might potentially be explained by modifier genes, as well as epigenetic variables. 39 Our in vitro study suggested that dys-regulated lncRNAs might act as epigenetic variables by regulating DCM pathways and participate in the progression of DCM induced heart failure. However, cell viability and bcl2/bax mRNA levels were not changed after siRNA-mediated lncRNAs knockdown in cardiomyocytes (see Supplementary material online, Figure S4 ). Regarding these results, we speculated that regulation of lncRNAs on cell apoptosis/cell viability might require stress-induced condition. Consistent with our hypothesis, it was reported that DCM-associated gene BAG3 mutations increased the susceptibility to apoptosis only under stress conditions, but not under physiological conditions. 40 Moreover, another study demonstrated that no morphological or functional phenotype changes in lncRNA Chaer KO hearts. However, cardiac hypertrophy in response to pressure overload following TAC surgery was significantly attenuated in Chaer-KO mice. 18 Unfortunately, as the HCMs derived from ScienCell Research Laboratories do not proliferate, we have just enough cells for qRT-PCR assay, but not enough cells for protein assay or any more mechanistic experiments. The detailed function and mechanisms of these lncRNAs in DCM are still unknown. In the future, the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) would be a good choice for cardiac-lncRNAs studying. 18 It also should be noted that these lncRNAs identified from DCM patients may also regulate the progression of non-DCM (such as ischaemic and hypertensive cardiomyopathies) induced heart failure. Recently, the complex roles of a single ncRNA in multiple cell types in the heart have been uncovered. For example, miR-21 has been reported to promote cardiac fibrosis and cardiac hypertrophy in fibroblasts. 6 However, in cardiomyocytes, miR-21 can protect cardiomyocytes against hypertrophy and apoptosis. 26, 41, 42 Interestingly, si-RP11-544D21.2 treatment led to upregulation of TNF signalling pathway and MAPK signalling pathway in HCMs, but led to down-regulation of the same pathways in HCFs. Moreover, RP11-544D21.2 not only manipulated DCM-associated genes in cardiomyocytes, but also regulated tube formation and cell migration in endothelial cells. These ncRNAs are intriguing subjects for future studies to understand complicated and coordinated regulation of ncRNAs in multiple cell types during cardiovascular diseases. TAF10, a subunit of the RNA polymerase II pre-initiation complex, was suggested to be the cause of some up-regulated lncRNAs. According to published papers, hepatocyte-specific inactivation of TAF10 leads to the down-regulation of most hepatocyte-specific genes during embryonic life, but not genes in the adult liver. 43 Thus, TAF10 was suggested to be an essential transcription factor during very early stages of mouse embryo development. 44 However, the roles of TAF10 in lncRNAs regulation or cardiovascular diseases are still unknown. Our data indicated that TAF10 might the target transcription factor for some up-regulated lncRNAs. Moreover, TAF10 is necessary but not sufficient for inducing certain lncRNAs indicated the involvement of other transcription factors. Therefore, additional efforts are needed to investigate the regulation between TAFs and lncRNAs in heart diseases.
One of the limitations of this study is novel transcripts cannot be identified by microarray. For example, in a previous study published by the Ounzain S group, 1,521 (86 up-regulated and 225 down-regulated) novel unannotated lncRNAs were identified in infarcted adult mouse heart. Moreover, of the 1,521 novel lncRNAs, $73% were mapped to the human genome. 45 RNA-sequencing and microarray technologies each have their advocates and limitations. In the future, the best approach is to apply RNA-sequencing and arrays in combination to large-scale clinical studies, where RNA-Seq with sufficient depth is first conducted to discover all of the transcriptome elements potentially relevant to the disease of study followed by high-throughput and reliable screening of these elements on thousands of patient samples using custom-designed arrays. In summary, we provided the cardiac lncRNA profiles of control and DCM patients. We name the most up-regulated lncRNA RP11-544D21.2 as DCM-related lncRNA, DCRL. This human-specific lncRNA significantly regulated DCM-associated genes in cardiomyocytes, and also effected tube formation and cell migration in endothelial cells. These insights could ultimately lead to novel therapeutic approaches targeting DCM induced heart failure.
